Valuation: Autolus Therapeutics plc

Market Cap 421M 368M 338M 315M 597M 40.03B 606M 4.06B 1.58B 19.66B 1.58B 1.54B 67.84B P/E 2026 *
-1.79x
P/E 2027 * -2.52x
Enterprise Value 381M 333M 306M 285M 541M 36.27B 549M 3.67B 1.43B 17.81B 1.43B 1.4B 61.47B EV / Sales 2026 *
2.96x
EV / Sales 2027 * 2.46x
Free-Float
3.32%
Yield 2026 *
-
Yield 2027 * -
1 week-0.63%
Current month-1.25%
1 month-9.71%
3 months+12.06%
6 months-15.51%
Current year-20.60%
1 week 1.55
Extreme 1.55
1.72
1 month 1.38
Extreme 1.38
1.76
Current year 1.18
Extreme 1.175
2.07
1 year 1.18
Extreme 1.175
2.7
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 31/08/2014
Chief Executive Officer 61 29/02/2016
Director of Finance/CFO 56 06/08/2023
Director TitleAgeSince
Chairman 61 30/09/2014
Director/Board Member 78 31/07/2014
Director/Board Member 71 28/02/2018
Date Insider Type Main position Quantity % Market Cap.
06-28Free

Director

79,167 0.0477%
06-28Free

Director

79,167 0.0477%
06-28Free

Director

79,167 0.0477%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.63%-32.77%-33.61% 421M
+4.73%+5.50%+19.45%-8.94% 66.56B
-1.93%+1.13%+55.67%+219.58% 57.64B
+1.07%+42.10%+42.10%+42.10% 42.24B
+3.45%+3.54%-49.20%-56.09% 39.09B
+3.04%+7.01%+62.26%-24.13% 31.91B
+10.01%+33.49%+163.41%-34.35% 31.65B
+2.68%+8.68%+71.42%+87.73% 23.35B
+2.87%+15.37%+10.72%+196.62% 18.92B
-0.13%+1.91%+67.83%+127.66% 17.17B
Average +2.58%+6.58%+41.09%+51.66% 32.9B
Weighted average by Cap. +2.77%+6.49%+44.20%+53.92%

Financials

2026 *2027 *
Net sales 129M 112M 103M 96.34M 183M 12.24B 185M 1.24B 482M 6.01B 483M 472M 20.74B 191M 167M 153M 143M 271M 18.18B 275M 1.84B 716M 8.93B 717M 701M 30.81B
Net income -242M -211M -194M -181M -343M -22.99B -348M -2.33B -905M -11.29B -907M -887M -38.97B -184M -161M -148M -138M -261M -17.5B -265M -1.77B -689M -8.59B -690M -675M -29.65B
Net Debt -39.53M -34.57M -31.73M -29.62M -56.13M -3.76B -56.96M -381M -148M -1.85B -148M -145M -6.38B 48.41M 42.34M 38.86M 36.28M 68.74M 4.61B 69.76M 467M 181M 2.26B 182M 178M 7.81B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
02/07/26 US$1.580 0.00% 1,442,602
01/07/26 US$1.580 -1.25% 698,723
30/06/26 US$1.600 -3.03% 1,067,957
29/06/26 US$1.650 +2.48% 959,824
26/06/26 US$1.610 +1.26% 771,902
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.580USD
Average target price
8.550USD
Spread / Average Target
+441.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock